advertisement
Groth SL 9
Showing records 1 to 9 |
Display all abstracts from Groth SL96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesBeykin G
American Journal of Ophthalmology 2021; 234: 223-234
96287 8-year follow-up of Excimer Laser Trabeculostomy Alone and Combined With Phacoemulsification in Patients with Open Angle GlaucomaBerlin MS
Journal of Cataract and Refractive Surgery 2022; 48: 838-843
96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesStell L
American Journal of Ophthalmology 2021; 234: 223-234
96287 8-year follow-up of Excimer Laser Trabeculostomy Alone and Combined With Phacoemulsification in Patients with Open Angle GlaucomaShakibkhou J
Journal of Cataract and Refractive Surgery 2022; 48: 838-843
96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesHalim MS
American Journal of Ophthalmology 2021; 234: 223-234
96287 8-year follow-up of Excimer Laser Trabeculostomy Alone and Combined With Phacoemulsification in Patients with Open Angle GlaucomaTilakaratna N
Journal of Cataract and Refractive Surgery 2022; 48: 838-843
96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesNuñez M
American Journal of Ophthalmology 2021; 234: 223-234
96287 8-year follow-up of Excimer Laser Trabeculostomy Alone and Combined With Phacoemulsification in Patients with Open Angle GlaucomaGiers U; Groth SL
Journal of Cataract and Refractive Surgery 2022; 48: 838-843
96331 Phase 1b Randomized Controlled Study of Short Course Topical Recombinant Human Nerve Growth Factor (rhNGF) for Neuroenhancement in Glaucoma: Safety, Tolerability, and Efficacy Measure OutcomesPopova L; Nguyen BT; Groth SL; Dennis A; Li Z; Atkins M; Khavari T; Wang SY; Chang R; Fisher AC; Sepah YJ; Goldberg JL
American Journal of Ophthalmology 2021; 234: 223-234
Issue 22-3
Change Issue
advertisement